Chemical manufacturer Epigral Ltd saw its shares tumble on Monday after posting a sharp decline in earnings for the quarter ended September 2025 (Q2 FY26).

The company’s net profit fell 37% year-on-year to ₹51.2 crore, compared with ₹81.3 crore in the same period last year.

Revenue from operations slipped 6.2% to ₹587.3 crore from ₹626 crore a year ago, while EBITDA declined 25.6% to ₹132 crore versus ₹178 crore in the corresponding quarter.

The company’s operating margin narrowed to 22.6% from 28.5%, reflecting weaker pricing trends and higher input costs.

Also Read: KPIT Tech Q2 Results: Stock gains after revenue growth, steady margins; Guidance awaited

Epigral is a speciality chemicals and chlor-alkali products manufacturer, catering to both domestic and international markets w

See Full Page